Prakhar Agrawal
Stock Analyst at Cantor Fitzgerald
(2.87)
# 1,225
Out of 4,667 analysts
43
Total ratings
27.78%
Success rate
4.9%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Prakhar Agrawal
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| MDGL Madrigal Pharmaceuticals | Reiterates: Neutral | n/a | $320.76 | - | 4 | Nov 20, 2024 | |
| KROS Keros Therapeutics | Reiterates: Overweight | n/a | $54.15 | - | 1 | Oct 24, 2024 | |
| ORIC ORIC Pharmaceuticals | Reiterates: Overweight | n/a | $8.79 | - | 5 | Sep 23, 2024 | |
| GPCR Structure Therapeutics | Reiterates: Overweight | $65 | $31.72 | +104.92% | 12 | Sep 23, 2024 | |
| MLTX MoonLake Immunotherapeutics | Reiterates: Overweight | n/a | $50.26 | - | 10 | Sep 23, 2024 | |
| AKRO Akero Therapeutics | Reiterates: Overweight | n/a | $30.57 | - | 5 | Jun 20, 2024 | |
| RAPT RAPT Therapeutics | Downgrades: Neutral | n/a | $1.04 | - | 2 | Feb 20, 2024 | |
| TGTX TG Therapeutics | Reiterates: Overweight | $24 | $34.63 | -30.69% | 2 | Apr 17, 2023 | |
| TCRT Alaunos Therapeutics | Assumes: Overweight | $450 | $2.15 | +20,830.23% | 1 | Jul 15, 2022 | |
| EQ Equillium | Initiates: Buy | $14 | $0.70 | +1,896.58% | 1 | Mar 3, 2021 |
Madrigal Pharmaceuticals
Nov 20, 2024
Reiterates: Neutral
Price Target: n/a
Current: $320.76
Upside: -
Keros Therapeutics
Oct 24, 2024
Reiterates: Overweight
Price Target: n/a
Current: $54.15
Upside: -
ORIC Pharmaceuticals
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $8.79
Upside: -
Structure Therapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: $65
Current: $31.72
Upside: +104.92%
MoonLake Immunotherapeutics
Sep 23, 2024
Reiterates: Overweight
Price Target: n/a
Current: $50.26
Upside: -
Akero Therapeutics
Jun 20, 2024
Reiterates: Overweight
Price Target: n/a
Current: $30.57
Upside: -
RAPT Therapeutics
Feb 20, 2024
Downgrades: Neutral
Price Target: n/a
Current: $1.04
Upside: -
TG Therapeutics
Apr 17, 2023
Reiterates: Overweight
Price Target: $24
Current: $34.63
Upside: -30.69%
Alaunos Therapeutics
Jul 15, 2022
Assumes: Overweight
Price Target: $450
Current: $2.15
Upside: +20,830.23%
Equillium
Mar 3, 2021
Initiates: Buy
Price Target: $14
Current: $0.70
Upside: +1,896.58%